Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
Rita Nanda(University of Chicago), Laura J. Esserman(University of California, San Francisco), Angela DeMichele(University of Pennsylvania), Richard B. Schwab(Center for Personalized Cancer Treatment), Andres Forero‐Torres(Kirklin Clinic), Laura van ‘t Veer, Erin D. Ellis(University of Hawaii Cancer Center), Adam L. Asare(Quantum Leap Healthcare Collaborative), Lajos Pusztai(Yale University), Scott Berry(Queen's University), Amy Wilson(Quantum Leap Healthcare Collaborative), Minetta C. Liu(Mayo Clinic), Teresa Helsten(University of California, San Diego), Tufia C. Haddad(Mayo Clinic), Ruby Singhrao(University of California, San Francisco), Judy C. Boughey(Mayo Clinic in Arizona), Douglas Yee(University of Minnesota Medical Center), Nola M. Hylton(University of California, San Francisco), Nora Jaskowiak(University of Chicago), Katherine Steeg(University of California, San Francisco), Erica Stringer-Reasor(University of Alabama at Birmingham), Smita Asare(Quantum Leap Healthcare Collaborative), Rebecca Shatsky(University of California San Diego), Ronald Cohen(University of Chicago), A. Jo Chien(University of California, San Francisco), Melanie Majure(University of California, San Francisco), Kathy S. Albain(Loyola University Chicago), Marie Catherine Lee(Moffitt Cancer Center), Christina Yau(Hospital Authority), Amy S. Clark(Abramson Center for Jewish Life), Jeffrey B. Matthews(University of California, San Francisco), Kathleen Kemmer(University of Michigan), Heather Han(Moffitt Cancer Center), Claudine Isaacs(Georgetown University), Jane Perlmutter(Gemini Computers (United States)), Donald A. Berry(Berry & Associates (United States)), Gillian L. Hirst(University of California, San Francisco), Hope S. Rugo(City of Hope), Anne M. Wallace(University of California San Diego), Anthony Elias(University of Colorado Cancer Center), Ashish Sanil(Berry & Associates (United States)), Michelle Melisko(University of California, San Francisco), Catherine Parker(National Cancer Institute), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center)
Cited by 707
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k